Liver cancer combo trial halted early – what it means

NCT ID NCT04050462

Terminated Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested whether adding either BMS-986253 or cabiralizumab to the immunotherapy drug nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. Only 13 participants were enrolled before the study was terminated. The goal was to see if the combinations improved response rates, but the early stop limits what can be concluded.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab combined with either BMS-986253 or cabiralizumab
What this could lead to: If successful, this could point toward a more effective combination therapy for advanced liver cancer that is not treatable with surgery.
What could go wrong: This was a very small, early-phase trial that was terminated early, so results are limited. The combinations may not work better than nivolumab alone and could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

NYU Langone Health

New York, New York, 10016, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.